SCAP and hypertriglyceridemia: The resulting phenotypes suggest that the inhibition of SREBP-2 or Scap in the liver, which reduces cholesterol and FA synthesis, may be therapeutically advantageous for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease.